ethyl 2-(2-methyl-3-nitrophenyl)acetate | 23876-17-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 2-(2-methyl-3-nitrophenyl)acetate
• 英文别名: 2-Methyl-3-nitrophenylacetic acid ethyl ester
• CAS: 23876-17-7
• 化学式: C₁₁H₁₃NO₄
• 分子量: 223.229
• InChiKey: XTIYTNIZPQPWAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 2-(2-methyl-3-nitrophenyl)acetate 在 sodium hydroxide 作用下， 生成 2-甲基-3-硝基苯乙酸
  参考文献：
  名称：

  3-硝基邻二甲苯的氧化和克莱森缩合产物

  摘要：

  当3-硝基-邻二甲苯用乙酸铬苯酯氧化时，远离硝基的甲基被攻击，生成2-乙酸-3-硝基亚苄基二乙酸酯。在克莱森缩合条件下，相邻的甲基与草酸二乙酯反应。产物氧化得到2-甲基-6-硝基苯基乙酸，经还原环化，得到4-甲基羟吲哚。

  DOI：

  10.1039/j39690001935
• 作为产物：
  描述：

  2-甲基-3-硝基苯甲醇 在 盐酸 作用下， 生成 ethyl 2-(2-methyl-3-nitrophenyl)acetate
  参考文献：
  名称：

  3-硝基邻二甲苯的氧化和克莱森缩合产物

  摘要：

  当3-硝基-邻二甲苯用乙酸铬苯酯氧化时，远离硝基的甲基被攻击，生成2-乙酸-3-硝基亚苄基二乙酸酯。在克莱森缩合条件下，相邻的甲基与草酸二乙酯反应。产物氧化得到2-甲基-6-硝基苯基乙酸，经还原环化，得到4-甲基羟吲哚。

  DOI：

  10.1039/j39690001935

文献信息

• Divergent Photocatalytic Reactions of α-Ketoesters under Triplet Sensitization and Photoredox Conditions
  作者：Jian Zheng、Xiao Dong、Tehshik P. Yoon

  DOI：10.1021/acs.orglett.0c02314

  日期：2020.8.21

  The long-lived triplet excited states of transition metal photocatalysts can activate organic substrates via either energy- or electron-transfer pathways, and the rates of these processes can be influenced by rational tuning of the reaction conditions. The characteristic reactive intermediates generated, however, are distinct and can exhibit very different reactivity patterns. This mechanistic diversity

  过渡金属光催化剂的长寿命三重激发态可以通过能量或电子转移途径激活有机底物，这些过程的速率可以通过反应条件的合理调整来影响。然而，生成的特征反应中间体是不同的，并且可以表现出非常不同的反应模式。因此，可用于光催化反应的这种机械多样性可能为设计发散反应提供了机会，这些反应在表面相似的条件下产生明显不同的化学结果。在这里，我们表明苯甲酰甲酸酯与烯烃的光催化反应可以分别在有利于能量转移或电子转移的条件下进行 Paternò-Büchi 环加成或烯丙基官能化反应。
• ESTER COMPOUND AND MEDICINAL USE THEREOF
  申请人：Japan Tobacco Inc.

  公开号：EP1479666A1

  公开（公告）日：2004-11-24

  A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1") (wherein    R1 and R2 are each hydrogen atom or optionally substituted aryl, etc.;    X is -COO- or -CON(R10)-;    R3 and R4 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.;    R5, R6 and R7 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.;    R8 and R9 are each independently hydrogen atom, C1-C6 alkyl, -CON(R18)(R19) or -COO(R20), etc.;    ring A, ring B and ring C are each independently aryl or heterocycle residue, etc.;    Alk1 and Alk2 are each independently alkanediyl, etc.;    l and m are each an integer of 0 or 1 to 3) or a prodrug thereof, or a pharmaceutically acceptable salt of either. The therapeutic agent selectively inhibits MTP in the small intestine, thus causes no such side effect as a fatty liver.

  一种治疗高脂血症的新型药物，其为酯化合物，由式(1")表示（其中：R1和R2均为氢原子或可选择取代的芳基等；X为-COO-或-CON(R10)-；R3和R4均为氢原子、C1-C6烷基或C1-C6烷氧基等；R5、R6和R7均为氢原子、C1-C6烷基或C1-C6烷氧基等；R8和R9各自独立地为氢原子、C1-C6烷基、-CON(R18)(R19)或-COO(R20)等；环A、环B和环C各自独立地为芳基或杂环残基等；Alk1和Alk2各自独立地为脂肪二亚基等；l和m均为0或1至3的整数），或其前药，或其药学上可接受的盐。该治疗剂能够选择性地抑制小肠中的MTP，因此不会引起脂肪肝等副作用。
• Ester compound and medicinal use thereof
  申请人：Hagiwara Atsushi

  公开号：US20050075367A1

  公开（公告）日：2005-04-07

  A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1″) (wherein R 1 and R 2 are each hydrogen atom or optionally substituted aryl, etc.; X is —COO— or —CON(R 10 )—; R 3 and R 4 are each hydrogen atom, C 1 -C 6 alkyl or C 1 -C 6 alkoxy, etc.; R 5 , R 6 and R 7 are each hydrogen atom, C 1 -C 6 alkyl or C 1 -C 6 alkoxy, etc.; R 8 and R 9 are each independently hydrogen atom, C 1 -C 6 alkyl, —CON(R 18 )(R 19 ) or —COO(R 20 ), etc.; ring A, ring B and ring C are each independently aryl or heterocycle residue, etc.; Alk 1 and Alk 2 are each independently alkanediyl, etc.; l and m are each an integer of 0 or 1 to 3) or a prodrug thereof, or a pharmaceutically acceptable salt of either. The therapeutic agent selectively inhibits MTP in the small intestine, thus causes no such side effect as a fatty liver.

  一种治疗高脂血症的新型药物，其为酯化合物，由式（1”）所表示（其中，R1和R2分别为氢原子或可选取代的芳基等；X为—COO—或—CON(R10)—；R3和R4分别为氢原子、C1-C6烷基或C1-C6烷氧基等；R5、R6和R7分别为氢原子、C1-C6烷基或C1-C6烷氧基等；R8和R9分别独立地为氢原子、C1-C6烷基、—CON(R18)(R19)或—COO(R20)等；环A、环B和环C分别独立地为芳基或杂环残基等；Alk1和Alk2分别独立地为脂肪二亚基等；l和m分别为0或1至3的整数），或其前药，或其药学上可接受的盐。该治疗剂能够选择性地抑制小肠中的MTP，从而不会引起脂肪肝等副作用。
• ESTER COMPOUND AND MEDICAL USE THEREOF
  申请人：Hagiwara Atsushi

  公开号：US20100158996A1

  公开（公告）日：2010-06-24

  A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1″) (wherein R 1 and R 2 are each hydrogen atom or optionally substituted aryl, etc.; X is —COO— or —CON(R 10 )—; R 3 and R 4 are each hydrogen atom, C 1 -C 6 alkyl or C 1 -C 6 alkoxy, etc.; R 5 , R 6 and R 7 are each hydrogen atom, C 1 -C 6 alkyl or C 1 -C 6 alkoxy, etc.; R 9 and R 9 are each independently hydrogen atom, C 1 -C 6 alkyl, —CON(R 18 ) (R 19 ) or —COO(R 20 ), etc.; ring A, ring B and ring C are each independently aryl or heterocycle residue, etc.; Alk 1 and Alk 2 are each independently alkanediyl, etc.; l and m are each an integer of 0 or 1 to 3) or a prodrug thereof, or a pharmaceutically acceptable salt of either. The therapeutic agent selectively inhibits MTP in the small intestine, thus causes no such side effect as a fatty liver.

  一种治疗高脂血症的新型药物，其为酯化合物，由式（1″）所表示（其中R1和R2分别为氢原子或可选择取代的芳基等；X为—COO—或—CON(R10)—；R3和R4分别为氢原子、C1-C6烷基或C1-C6烷氧基等；R5、R6和R7分别为氢原子、C1-C6烷基或C1-C6烷氧基等；R8和R9分别独立地为氢原子、C1-C6烷基、—CON(R18)(R19)或—COO(R20)等；环A、环B和环C分别独立地为芳基或杂环残基等；Alk1和Alk2分别独立地为脂肪二亚基等；l和m分别为0或1至3的整数），或其前药，或其药学上可接受的盐。该治疗剂选择性地抑制小肠中的MTP，从而不会引起脂肪肝等副作用。
• 1,3-dichloro-5,5-dimethylhydantoin promoted esterification of carboxylic acids under mild conditions
  作者：Qing Dong、Qingqiu Huang、Mengke Wang、Hongyan Chen、You Zi、Weichun Huang

  DOI：10.1016/j.tetlet.2022.154226

  日期：2022.12

  novel and practical method has been discovered for the synthesis of esters from carboxylic acids promoted by 1,3-dichloro-5,5-dimethylhydantoin. Reactions proceed smoothly under mild conditions and show high efficiency with good to excellent yields. A series of carboxylic acids including simple molecules, drugs and amino acids are applicable to this method.

  已发现一种新颖实用的方法，用于由 1,3-二氯-5,5-二甲基乙内酰脲促进的羧酸合成酯。反应在温和条件下顺利进行，效率高，产率高。包括简单分子、药物和氨基酸在内的一系列羧酸都适用于该方法。